UCB Inspired by patients.Driven by science.

9 month interim report

Brussels, 30 October 2018

9M 2018 reportDisclaimer and safe harbor 2

Forward-looking statementsThis presentation contains forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “intends”,“plans”, “seeks”, “estimates”, “may”, “will”, and “continue” and similar expressions. These forward-looking statements are based on current plans, estimates andbeliefs of management. By their nature, such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks,uncertainties, and assumptions which might cause the actual results, financial condition, performance or achievements of UCB, or industry results, to be materiallydifferent from any future results, performance, or achievements expressed or implied by such forward-looking statements contained in this presentation.

Important factors that could result in such differences include but are not limited to: changes in general economic, business and competitive conditions, the inability toobtain necessary regulatory approvals or to obtain them on acceptable terms, costs associated with research and development, changes in the prospects forproducts in the pipeline or under development by UCB, effects of future judicial decisions or governmental investigations, product liability claims, challenges to patentprotection for products or product candidates, changes in laws or regulations, exchange rate fluctuations, changes or uncertainties in tax laws or the administration ofsuch laws and hiring and retention of its employees. There is no guarantee that new product candidates in the pipeline will progress to product approval or that newindications for existing products will be developed and approved. Products or potential products which are the subject of partnerships, joint ventures or licensingcollaborations may be subject to differences between the partners. Also, UCB or others could discover safety, side effects or manufacturing problems with itsproducts after they are marketed. Moreover, sales may be impacted by international and domestic trends toward managed care and health care cost containmentand the reimbursement policies imposed by third-party payers as well as legislation affecting biopharmaceutical pricing and reimbursement.

Given these uncertainties, the public is cautioned not to place any undue reliance on such forward-looking statements. These forward-looking statements are madeonly as of the date of this presentation. UCB expressly disclaims any obligation to update any such forward-looking statements in this presentation to reflect anychange in its expectations with regard thereto or any change in events, conditions, for circumstances on which any such statement is based, unless such statement isrequired pursuant to applicable laws and regulations.

In the event of any differences between this Presentation and the Annual or Half Year Report, the information included in the Report shall prevail.

9M 2018 reportUCB's patient value strategy 3

Our ambition is to be the patient preferred biotech leader,

creating patient value for specific populations through unique outcomes, the best experience and improving as

many of these lives as possible.

This will lead to sustainable growthfor UCB and its shareholders.

Value for patients

Mariana, living with epilepsy

Value for shareholders

9M 2018 reportDriving value for patients 4

Progress towards higher patient value

From Patient to ScienceCimzia® women of child bearing age approval

UCB0107 (anti-Tau antibody) first in human

From Science to SolutionRozanolixizumab discovery driven by patient experiences with outpatient treatment

From Solution to PatientThanks to innovative extrapolation, faster access for epilepsy patients for Briviact® (pediatric) and Keppra® (China)

Acquisition of midazolam nasal spray in the treatment of acute repetitive seizures (ARS) in patients with epilepsyPartnership with Sciences 37 to bring clinical studies directly into patient’s home

9M 2018 reportUCB is progressing on our strategic growth path 5

Refer to slides in the appendix for further details

Grow core productsCimzia®, Vimpat®, Keppra®, Briviact® + Neupro®

combined net sales: € 2.78 billion (+6%; +12% CER)

Advance and prepare launch of next wavePhase 3 program for bimekizumab in psoriasis startedEvenity™ resubmission to U.S. FDAmidazolam filing (U.S.)

Deliver breakthrough solutionsdapirolizumab pegol Phase 2b topline results in lupusrozanolixizumab Phase 2a topline results in myasthenia gravisUCB0107 (anti-Tau antibody) first in human

Continued focusCreation of Syndesi + investment in CeribellAcquisitions of Element Genomics + midazolam nasal spray

Grow & Prepare

2015

Accelerate & Expand

2019

Breakthrough & Lead

2022

2018 financial outlook confirmed

Achievements 2018 vs. priorities – well on track

9M 2018 reportGrow core products 6

On track to deliver FY 2018 guidance

Numbers may not add due to roundingCER: constant exchange rate

€ million 9M 2018 9M 2017 Act CER

Revenue 3 441 3 331 3% 6%

Immunology 1 052 1022 3% 9%

Cimzia® 1 052 1022 3% 9%

Neurology 1 728 1601 8% 14%Vimpat® 795 707 13% 19%

Keppra® 608 607 0% 5%

Briviact® 97 57 70% 81%

Neupro® 228 230 -1% 2%

Combined net sales:€ 2.78 billion

(+6%; +12% CER)

Adjusted for allergy drugdivestiture: +5%; +8% CER

9M 2018 reportIncreasing value of UCB's early and late-stage pipeline 7

Driven by strong UCB science and technology platforms

dapirolizumabpegol

systemic lupus erythematosus

padsevonilepilepsy

rozanolixizumabmyasthenia gravis

immune thrombocytopenia

UCB7858

UCB6673

UCB0599

Phase 2b / Phase 3

Phase 1

UCB0159

Phase 2a

UCB0107

Seletalisib in Sjogren's Syndrome and APDS (phase 2a and phase 1b) deprioritized UCB4144/VR942 available for license

radiprodilinfantile spasm

Filing

romosozumabosteoporosis

midazolamnasal spray - acute repetitive seizures

neurologyimmunologybone

bimekizumabpsoriasis, psoriatic arthritis

ankylosing spondylitis

9M 2018 reportContinued focus 8

Complement & share

Acquisitions Spin offs

midazolamnasal spray in epilepsy

StrideBio, Inc.

UCB acquired rights to midazolam nasal spray from Proximagen in April 2018UCB invested in Ceribell in September 2018

VenturesInvestment

Rapid Response EEG System

9M 2018 report2018 and mid-term guidance confirmed 9

Maximize (new) growth drivers and strengthen sustainability

rEBITDA: recurring Earnings Before Interest, Taxes, Depreciation and Amortization charge* ~188 million shares weighted average outstanding

2018 financial targets Mid-term guidance

Revenue € 4.5 - 4.6 billion• Continued strong core product growth

• Currency exchange impact

rEBITDA / revenue ratio of 31% in 2021UCB investing into the pipeline complemented with inorganic growth opportunities

rEBITDA € 1.3 – 1.4 billion• R&D expense ratio of ~26% (+/-1% point)

• Launch preparation

Peak sales• 'CVN' combined > € 3.1 billion by 2020

• Briviact® > € 600 million in 2026

Core EPS* € 4.30 – 4.70• Expected underlying tax ratio

in the "low twenties"

9M 2018 reportAdvance and prepare launch of next products 10

Delivering on strategy, growth and profitability targets

The trademark Evenity™ is provisionally approved for use by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Evenity™ (romosozumab) is developed in partnership with Amgen globally.UCB acquired rights to midazolam nasal spray from Proximagen in April 2018

Phase 3 program completed

Regulatory review•U.S. – resubmission of the Biologics License Application (July 2018)

•EU (Jan. 2018)

•CDN, JP, AU, BR, CH

Evenity™(romosozumab)

Phase 2b program completed

Phase 3 • psoriasis: ongoing

(results Q4 2019)

• psoriatic arthritis to start (Q4 2018)

• ankylosing spondylitis to start (Q4 2018)

bimekizumab

Phase 2a program completed

Phase 2b ongoing• highly drug-resistant

epilepsy

• start: Feb. 2018 (results H1 2020)

padsevonil

Acquired: Phase 3 program completed

Regulatory review• U.S. filing (Aug 2018)

• orphan drug + fast track designation granted

midazolamnasal spray

Proof of concept achieved

Phase 2 ongoing• myasthenia gravis

results (Oct 2018)

• immune thrombocytopenia (ITP) (results Q4 2018)

• CIDP to start Q1 2019

rozanolixizumab

Sustainable top and bottom line growth delivered over the last years Profitability target achieved ahead of time in 2017 Strong foundation enabling future growth and investments in innovation

CIDP: Chronic inflammatory demyelinating polyneuropathy

Further factsand figures

11

9M 2018 reportGrow core products 12

2018 lifecycle management milestones

WOCBA: women of child bearing age Nr axSpA: non radiographic axial spondyloarthritisPsO: psoriasis PsA: psoriatic arthritisPOS: partial onset seizures, also known as focal seizures GTCS: primary generalized tonic-clonic seizures

Cimzia® Vimpat® Keppra® Briviact® Neupro®

• WOCBA label extension (EU – Jan / U.S. – Mar / Japan – Sept)

• Psoriasis (U.S. – May / EU – June)

• AutoClick® (Japan – Aug)

• Epilepsy GTCS (China – May)

• Epilepsy monotherapy (China – July)

• Epilepsy POS: pediatric (U.S. – May / EU – July)

• Parkinson’s disease (China – July)

• Rheumatoid arthritis (China – Mar)

• Nr axSpA³ (U.S. – Sept)

• Epilepsy POS (Japan): o pediatric (incl. dry syrup

formulation - Jan) o IV formulation (Jan)

• Epilepsy POS (China): o pediatric (incl. oral

formulation - Sept) o IV formulation (Sept)

• Nr axSpA³: Phase 3 results (U.S. – May)

• PsO4 / PsA: Phase 3 results (Japan – Sept)

• Acute repetitive seizures: Phase 2 results (July)

9M 2018 reportCimzia® performance 13

Sustainable growth in all regions

1 Numbers may not add due to rounding 2 nr axSpA: non-radiographic axial spondyloarthritisCER: constant exchange rates

Label extension to include WOCBA (EU / U.S. / Japan) Psoriasis: approval (U.S. & EU) AutoClick®: approval (Japan) Nr axial spondyloarthritis²: Phase 3 results & filing (U.S.) Psoriasis / psoriatic arthritis: Phase 3 results (Japan)

• Loss of exclusivity (U.S. & EU)

• Loss of exclusivity(Japan)

2018 2024 2026

For patients living with• Rheumatoid arthritis• Psoriatic arthritis• Psoriasis• Ankylosing spondylitis /

axial spondyloarthritis• Crohn’s disease

Net sales1

€ million 9 M 2018 9M 2017 Act CER

U.S. 652 656 -1% 7%

Europe 294 271 9% 9%

International markets 106 95 11% 22%

Total Cimzia® 1 052 1 022 3% 9%

9M 2018 reportCimzia® in-market performance 14

1 In-market growth is calculated for MAT period ; US, Europe & Japan : MAT Aug 2018 vs MAT Aug 20172 Market share is calculated for R3M period

6.3%

5.5%

6.0%

6.5%

7.0%

Aug-17 Nov-17 Feb-18 May-18 Aug-18

Cimzia® RheumatologyR3M Patient Share 2

2.6%6.7%

10.0%

0%

5%

10%

15%

20%

Anti TNF Biologics Cimzia®

Cimzia® vs. Rheumatology Market Growth 1

U.S.

+7.4%

+0.3%

Source: U.S: IQVIA Source of Business Report Aug 2018

3.2%6.3%

10.3%

0%

5%

10%

15%

20%

Anti TNF Biologics Cimzia®

Cimzia® vs. RA Market Growth 1

10.4%12.0%

9.1%

0%

5%

10%

15%

20%

Anti TNF Biologics Cimzia®

Cimzia® vs. RheumatologyMarket Growth 1

Europe Japan

8.3%

7.5%

8.0%

8.5%

9.0%

Aug-17 Nov-17 Feb-18 May-18 Aug-18

Cimzia® RheumatologyR3M Patient Share 2

Source: IMS MIDASIn-Market KPI’s are based on Exit Patients

+7.1%

4.4%

3.5%

4.0%

4.5%

5.0%

Aug-17 Nov-17 Feb-18 May-18 Aug-18

Cimzia® RA R3M Patient Share 2

+0.3%

Source: IMS MIDAS; Cimzia® patients are considered 100% in RAIn-Market KPI’s are based on Exit Patients

-1.3%

9M 2018 reportVimpat® 15

Strong growth in all markets

1 Numbers may not add due to rounding 2 POS: Partial-onset seizures, also known as focal seizuresCER: constant exchange rate 3 PGTCS: Primary Generalized Tonic-Clonic Seizures

• PGTCS3: Phase 3 results

• Patent expiry (U.S. & EU)

• Loss of exclusivity(Japan)

2019 20242022

For patients living with• Epilepsy – POS2

• Adults, adolescents and children from 4 years of age (EU & U.S.)

• Adults (Japan)

Net sales1

€ million 9 M 2018 9M 2017 Act CER

U.S. 589 540 9% 17%

Europe 152 128 19% 19%

International markets 54 39 39% 50%

Total Vimpat® 795 707 13% 19%

2018

POS2 pediatric (incl. dry syrup formulation): filing (Japan)

IV formulation: filing (Japan) POS2 pediatric (incl. oral solution):

submission (China) IV formulation: submission (China) U.S. Court of Appeals confirms

validity of patent

9M 2018 report

4.0%

3.0%

3.2%

3.4%

3.6%

3.8%

4.0%

Aug-17 Nov-17 Feb-18 May-18 Aug-18

Vimpat® – R3M TDx Share

4.4%

3.8%

4.0%

4.2%

4.4%

4.6%

4.8%

Aug-17 Nov-17 Feb-18 May-18 Aug-18

Vimpat® – R3M TRx Share

1.1%

7.9%

0%

5%

10%

15%

20%

AED Market Vimpat®

Vimpat® vs. AED Market Growth (TRx)

5.6%

0%

5%

10%

AED Market Vimpat®

-2.1%

18.8%

-5%

0%

5%

10%

15%

20%

AED Market Vimpat®

Vimpat® vs. AED Market Growth (TDx)

Vimpat® in-market performance 16

AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In Europe and Japan, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.

U.S.

+6.8%

+0.3%

Europe Japan

Source data U.S.: U.S. IMS NPA - In-Market KPIs are based on TRx

+20.9%

+0.8%

Source data EU: IMS MIDAS - In-Market KPI’s are based on TDx Source data JP: IMS MIDAS - In-market KPI’s are based on TDx

2.2%

0.0%

0.5%

1.0%

1.5%

2.0%

2.5%

Aug-17 Nov-17 Feb-18 May-18 Aug-18

Vimpat® – R3M TDx Share

+419%

+1.6%

424.9%

420%

425%

430% Vimpat® vs. AED Market Growth (TDx)

9M 2018 reportKeppra® 17

Reflecting both, the established brand and the maturity

1 Numbers may not add due to rounding POS: Partial-onset seizures, also known as focal seizuresCER: constant exchange rate PGTCS: Primary Generalized Tonic-Clonic Seizures

GTCS: Generalized Tonic-Clonic Seizures

• Patent expiry(Japan)

2020

For patients living with• Epilepsy – POS• Epilepsy – PGTCS• Epilepsy myoclonic

seizures

Net sales1

€ million 9M 2018 9M 2017 Act CER

U.S. 168 173 -3% 4%

Europe 168 178 -6% -5%

International markets 272 256 6% 13%

Total Keppra® 608 607 0% 5%

Epilepsy GTCS: approval (China)

Epilepsy monotherapy: approval (China)

2018

9M 2018 report

-2.1% -2.4%

-15%

-10%

-5%

0%AED Market Keppra®

Keppra® vs. AED Market Growth (TDx)

12.2%

11.0%

11.5%

12.0%

12.5%

13.0%

13.5%

Aug-17 Nov-17 Feb-18 May-18 Aug-18

Keppra® – R3M TDx Share

0.7%

0.0%

0.5%

1.0%

1.5%

2.0%

2.5%

Aug-17 Nov-17 Feb-18 May-18 Aug-18

Keppra® – R3M TRx Share

1.1%

-11.8%-15%

-10%

-5%

0%

5%

AED Market Keppra®

Keppra® vs. AED Market Growth (TRx)

5.6%

20.6%

0%

5%

10%

15%

20%

25%

AED Market Keppra®

Keppra® vs. AED Market Growth (TDx)

Keppra® in-market performance 18

AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In Europe and Japan, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.

U.S.

-12.9%

-0.1%

Europe Japan

Source data U.S.: U.S. IMS NPA - In-Market KPIs are based on TRx

-0.3%

-0.3%

Source data EU: IMS MIDAS - In-Market KPI’s are based on TDx Source data JP: IMS MIDAS - In-market KPI’s are based on TDx

16.6%

14.5%

15.0%

15.5%

16.0%

16.5%

17.0%

Aug-17 Nov-17 Feb-18 May-18 Aug-18

Keppra® – R3M TDx Share

+15%

+1.6%

9M 2018 reportBriviact® 19

Strong U.S. growth

1 Numbers may not add due to rounding 2 POS: Partial-onset seizures, also known as focal seizuresCER: constant exchange rate Acute repetitive seizures study NCT03021018

• Epilepsy POS2

Phase 3 results (Japan)

2021

For patients living with• Epilepsy – POS2

• Adults, adolescents and children from 4 years of age (EU & U.S.)

Net sales1

• Patent expiry (U.S. & EU)

€ million 9M 2018 9M 2017 Act CER

U.S. 75 40 85% 99%Europe 20 16 27% 28%International markets 2 1 > 100% > 100%Total Briviact® 97 57 70% 81%

20262018

POS2: pediatric approval (U.S. & EU)

Acute repetitive seizures: Phase 2 results

9M 2018 reportBriviact® in-market performance 20

A new therapeutic option in the AED market

AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In EU, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.

U.S. Europe

Source data U.S.: U.S. IMS NPAIn-Market KPIs are based on TRx

Source data EU: IMS MIDASIn-Market KPI’s are based on TDx

0.33%

0.00%

0.20%

0.40%

0.60%

0.80%

1.00%

Aug-17 Nov-17 Feb-18 May-18 Aug-18

Briviact® – R3M TRx Share

0.72%

0.00%

0.20%

0.40%

0.60%

0.80%

1.00%

Aug-17 Nov-17 Feb-18 May-18 Aug-18

Briviact® – R3M TDx Share

+0.1%

+0.3%

9M 2018 reportNeupro® 21

Stable at constant exchange rates

1 Numbers may not add due to rounding CER: constant exchange rate

For patients living with• Parkinson’s disease• Restless legs syndrome

Net sales1

• Patent expiry (Japan)

2024

€ million 9M 2018 9M 2017 Act CER

U.S. 68 72 -6% 1%

Europe 127 122 4% 5%

International markets 33 35 -7% -2%

Total Neupro® 228 230 -1% 2%

• Patent expiry (U.S. & EU)

20212018

Parkinson’s disease: approval (China)

9M 2018 report

4.8% 5.4% 5.1%

-5%

0%

5%

10%

15%

20%

PD Market PD keycompetitors

Neupro®

Neupro® PD vs. PD (KC) Market Growth (TDx)

16.0%

15.0%

15.5%

16.0%

16.5%

Aug-17 Nov-17 Feb-18 May-18 Aug-18

Neupro® PD – R3M TDx Share

6.2%

6.0%

6.5%

7.0%

7.5%

Aug-17 Nov-17 Feb-18 May-18 Aug-18

Neupro® PD – R3M TRx Share

-0.2% -0.2%-3.4%

-5%

0%

5%

10%

15%

20%

PD market PD keycompetitors

Neupro®

Neupro® PD vs. PD (KC) Market Growth (TRx)

0.8%

-0.9%

17.1%

-5%

0%

5%

10%

15%

20%

PD Market PD keycompetitors

Neupro®

Neupro® PD vs. PD (KC) Market Growth (TDx)

Neupro® in-market performance 22

AED market: All molecules in ATC3= N3A + Phenobarbital in N5B. In Europe and Japan, the TDx of all these molecules are factored for epilepsy usage. In the U.S., the TRx of 26 of these molecules are factored for epilepsy usage.

U.S.

-3.2%

-0.4%

Europe Japan

Source data U.S.: U.S. IMS NPA - In-Market KPIs are based on TRx

-0.3%

+0.5%

Source data EU: IMS MIDAS - In-Market KPI’s are based on TDx Source data JP: IMS MIDAS - In-market KPI’s are based on TDx

34.7%

25.0%27.0%29.0%31.0%33.0%35.0%37.0%

Aug-17 Nov-17 Feb-18 May-18 Aug-18

Neupro® PD – R3M TDx Share

+18%

+5.9%

9M 2018 report

Translating scientific hypotheses into clinical development23

Evenity™ (romosozumab)osteoporosis

midazolam nasal spray acute repetitive seizures

bimekizumab (IL17A/F)psoriasispsoriatic arthritisankylosing spondylitis

Phase 3 program results Q4 2019Phase 3 to start Q4 2018Phase 3 to start Q4 2018

dapirolizumab pegol (CD40L antibody)systemic lupus erythematosus Phase 2b results (Oct 2018 - partner: Biogen)

padsevonil (PPSI)highly drug-resistant epilepsy Phase 2b results H1 2020

rozanolixizumab (FcRn)myasthenia gravisimmune thrombocytopeniaCIDP

Phase 2a results (Oct 2018)Phase 2a results Q4 2018Phase 2 to start Q1 2019

UCB6673 UCB7858 UCB0159

UCB0599 UCB0107 radiprodil (UCB3491)

FilingPhase 3Phase 2Phase 1

Bone

Immunology

Neurology

Evenity™ is the trade name of romosozumab which has been provisionally approved bythe U.S. Food & Drug Administration (FDA) and the European Medicines Agency (EMA).CIDP: Chronic inflammatory demyelinating polyneuropathy

Changes since February 2018:• Midazolam acquired (April 2018) & filed (August 2018) ● UCB4144/VR942 available for license• Seletalisib in Sjögren's Syndrome and APDS deprioritized ● UCB0107 first in human

9M 2018 reportR&D milestones

SLE: Systemic Lupus ErythematosusITP: Immune thrombocytopenia

24

dapirolizumab pegolSLE

Phase 2b results

rozanolixizumabmyasthenia gravisPhase 2a results

padsevonilhigh drug resistant

epilepsyPhase 2b start

bimekizumab psoriasis

Phase 3 results

padsevonilhigh drug resistant

epilepsyPhase 2b results

seletalisib

romosozumabosteoporosis in

post-menopausal women

filing (EU)

bimekizumab psoriatic arthritis

Phase 3 start

bimekizumab ankylosing spondylitis

Phase 3 start

neurologyimmunologybone

UCB0107Phase 1 start

rozanolixizumabITP

Phase 2a results

romosozumabresubmission

(U.S.)

midazolamepilepsy

filing (U.S.)

2018 2019 2020

rozanolixizumabCIDP

Phase 2 start

rozanolixizumabmyasthenia gravisconfirmatory phase

start

9M 2018 reportEvenity™ (romosozumab) 25

An innovative investigational bone-forming therapy

STRUCTURE, FRAME, BRIDGE and ARCH• Phase 3 studies completed

Opportunity to build new bone and slow bone loss in osteoporosis patients at imminent risk of fragility fractures

Dual effect on bone - increases bone formation and decreases bone resorption

Under regulatory review in the U.S., Canada, Japan, Australia, Braziland EU, Switzerland

• UCB and Amgen resubmitted Biologics License Application (BLA) to the U.S. FDA (July 2018)

Manorama, living with osteoporosis

The trademark EVENITY™ is provisionally approved for use by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).EVENITY™ (romosozumab) is developed in partnership with Amgen globally.

9M 2018 report

Translating scientific hypotheses into clinical differentiation26

Dual blockade of IL-17F and IL-17A by bimekizumab

Dual blockade of IL-17F on top of IL-17A

will improve therapeutic efficacy versus targeting IL-17A alone

IL-17F

IL-17RAIL-17RC

IL-17A

Bimekizumab specifically and completely blocks IL-17F and IL-17A

IL-17F and IL-17A are twin cytokines

driving joint and skin inflammation

9M 2018 report

• 560 patients living with psoriasis1

• 52 weeks

• ustekinumab• placebo

• PASI90 response• IGA 0/1 response

Phase 3BE VIVID / PS0009

(NCT03370133)

Start Dec. 2017Results: Q4 2019

Bimekizumab Phase 3 development program in psoriasis 27

3 / 4 trials against active comparators -designed to demonstrate superiority

1 moderate to severe chronic plaque psoriasis IGA: Investigator's Global AssessmentPASI90: Patients experiencing at least 90% skin clearance Source: www.clinicaltrial.govPASI100: Patients experiencing 100% skin clearance

• 400 patients living with psoriasis1

• 56 weeks

• placebo

• PASI90 response• IGA 0/1 response

Phase 3BE READY / PS0013

(NCT03410992)

Start Feb. 2018Results: Q4 2019

Duration

Comparator

Primary endpoints@ week 16

• 700 patients living with psoriasis1

• 48 weeks

• secukinumab

• PASI100 response

Phase 3bBE RADIANT / PS0015

(NCT03536884)

Start June 2018Results: 2020

• 450 patients living with psoriasis1

• 56 weeks

• adalimumab

• PASI90 response• IGA 0/1 response

Phase 3BE SURE / PS0008

(NCT03412747)

Start Jan. 2018Results: Q4 2019

9M 2018 report

•400 patients with drug-resistant focal epilepsy• failed with ≥ 4 AED•experiencing ≥4 seizures / month

•padsevonil / placebo (5 arms)

•Seizure frequency• from baseline over the 12 week maintenance period (U.S., Japan)

• 75% responder rate (EU)

•55 patients with highly drug-resistant focal epilepsy• failed with ≥4 AED•experiencing ≥4 seizures / week

•padsevonil / placebo (2 arms)

•75 % responder rate* 31% padsevonil11% placebo

Padsevonil Phase 2 program in drug-resistant focal epilepsy 28

Patient sub-group with high unmet medical need

* Proportion of subjects who achieve ≥75 % reduction in focal seizure frequency

Comparator

Endpoints

Phase 2a(NCT02495844 / EP0069 )

Phase 2b (NCT03373383 / ARISE / EP0091)

Results H1 2020AES 2017

9M 2018 report

• 43 patients with moderate to severe MG

• diagnosis of myasthenia gravis @ screening• be considered for treatment with

immunological therapy

• 99 days

• placebo (2 arms)

• Change from baseline in Quantitative Myasthenia Gravis (QMG) score to visit 9 (day 29)

• Change from Baseline in Myasthenia Gravis-Composite score to Visit 9

• Change from Baseline in Myasthenia Gravis-Activities of Daily Living (MGADL) score to Visit 9

Rozanolixizumab Phase 2a development programA first-in-class SubQ treatment for IgG-mediated diseases

subQ: sub-cutaneousIgG: immunoglobulin

Headline results (Oct 2018)

• 66 patients with primary ITP

• ≥ 3 months diagnosis @ screening• Platelet count <30x109/L @ screening and

<35x109/L @ baseline

• 12 weeks

• 5 arms

• Subjects experiencing at least one Treatment Emergent Event (TEAE) during the study

Comparator

Endpoints

Immune thrombocytopenia(NCT02718716)

Myasthenia gravis (NCT03052751)

Results Q4 2018interim results at ASH 2017

Duration

29

Study design currently discussed with health authorities

Chronic inflammatorydemyelinating

polyneuropathy

Phase 2 to start Q1 2019

9M 2018 report

Myasthenia gravis Immune thrombocytopenia Chronic inflammatory demyelinating polyneuropathy

• Antibodies target receptor sites of the neuromuscular junction

• Antibodies target platelets and destroy them

• Antibodies target components of peripheral nerves, causing damage to the myelin sheath

• Fatigue• Muscle weakness (eyes, neck and

jaws, respiratory muscles)

• Bruising• Nosebleeds• Purpura• Intracranial bleeding

• Motor deficits• Sensory deficits

• ~ 10 - 45 cases / 100 000 • ~ 10 - 60 cases / 100 000 • ~ 1 - 6 cases / 100 000

• Steroids• Plasma exchange (PEX)• IV immunoglobulin (IVIg)• Surgery (thymectomy)

• Corticosteroids & thrombopoeitin• IV immunoglobulin (IVIg)• Surgery (splenectomy)

• Corticosteroids• Plasma exchange (PEX)• IV / subQ immunoglobulin

Rozanolixizumab potential in multiple IgG autoantibody-mediated diseases with high unmet medical need

30

IV: IntravenoussubQ: sub-cutaneous

Current treatments partially stabilize the condition yet invasive, burdensome to patients & healthcare systems

9M 2018 report

Now first in human: UCB0107, an anti-Tau antibody forProgressive Supranuclear Palsy & Alzheimer’s disease

31

Source: UCB internal data AD: Alzheimer’s diseasePSP: Progressive Supranuclear Palsy

•Tau misfolding and aggregation leads to neuronal death and disease spread

•PSP is a rare, rapidly progressing tauopathy with debilitating cognitive & motor symptoms

•Alzheimer’s Disease is also a tauopathy, with high prevalence and economic impact

UCB0107 blocks tau uptake and aggregation

Key facts Key insights

Tau seeds spread from dying cells to

infect other neurons

UCB0107 was generated to block spreading of tau

seeds from patient materials

AD

PSP

Tau seed

9M 2018 reportTau misfolding leads to neuronal death and disease spread in AD and PSP

32

Microtubules stabilized by tau

Hyperphosphorylation of tau causing destabilization

of microtubules

Release and accumulation of

hyperphosphorylated tau

Release of tau seeds

Formation of tau oligomers

Formation of neurofibrillary tangles (NFTs)

Source: UCB internal data AD: Alzheimer’s diseasePSP: Progressive Supranuclear Palsy

9M 2018 reportTargeting tau spreading in early disease can delay or stop progression in AD and PSP

33

9M 2018 reportHY 2018 financials – foundation for FY 2018 34

Core product growth drive top and bottom line

CER: constant exchange rate*one-time other revenue of € 56 million for out-licensing the OTC-allergy drug Xyzal® (levoceterizine) in 2017

CER

+6%

+12%+7%

Actual

Revenue• Revenue (adjusted for one-time revenue*) € 2.27 billion• Net sales € 2.15 billion (+5%, +10% CER)

€ 2.27 billion

Total operating expenses • Overall operating expense ratio improved to 46%• R&D expenses phasing

€ 1.04 billion

Recurring EBITDA • Higher gross profit • Improved operating expenses ratio

€ 794 million

Profit of the Group• € 551 million attributable to UCB shareholders (+28%)

€ 574 million

Core earnings per share Based on 188 million weighted average shares outstanding (2017: 188 million)

€ 3.09

+2%

+27%

+22% +27%

-1% +4%

+4%

adjusted

+33%

+16%

9M 2018 reportCore product growth 35

Cimzia®, Vimpat®, Keppra®, Briviact® + Neupro® = 87% of net sales

CER = constant currency exchange rates* Excluding € 65 million hedging

Cimzia® +2% (+11% CER)• Sustainable growth in all regions

Vimpat® +10% (+20% CER)• Strong growth in all markets

Keppra® -5% (+2% CER)• Reflecting both, the established brand

and the maturity

Briviact® € 60 million• Strong U.S. growth

Neupro® -4% (0% CER)• Stable at constant exchange rates

HY 2018 net sales*€ 2 081 million

(+2%; CER: +10%)

9M 2018 report2018 HY report: recurring EBITDA 36

Solid growth - Improved operating expenses ratio

Numbers may not add due to rounding EBIT: Earnings before interest and taxesCER: constant exchange rate EBITDA: Earning before interests, taxes, depreciation and amortization charges

For the six months ended 30 June Actual Variance

€ million 2018 2017 Actual rates CER

Revenue 2 269 2 230 2% 6% Net sales 2 146 2 036 5% 10% Royalty income and fees 56 58 -4% 6% Other revenue 67 136 -50% -50%

Gross profit 1 696 1 666 2% 7% Marketing and selling expenses -442 -464 -5% 2% Research and development expenses -500 -474 5% 9% General and administrative expenses -88 -93 -5% -2% Other operating income / expenses (-) -9 -16 -48% -42%

Total operating expenses -1 039 -1 047 -1% 4%

Recurring EBIT (REBIT) 657 619 6% 11% Amortization of intangible assets 79 78 2% 6% Depreciation charges 58 45 29% 36%

Recurring EBITDA (REBITDA) 794 742 7% 12%

9M 2018 report2018 HY report: profit 37

Numbers may not add due to roundingCER: constant exchange rateEBIT: Earnings before interest and taxes

For the six months ended 30 June Actual Variance

€ million 2018 2017 Actual rates CER

Recurring EBIT 657 619 6% 11% Impairment charges 0 4 -100% -100% Restructuring expenses -4 -7 -41% -39% Gain on disposals 0 0 N/A N/A Other non-recurring income / expenses (-) 23 3 > 100% > 100%

Total non-recurring income / expenses (-) 19 1 > 100% > 100%

EBIT (operating profit) 676 619 9% 14% Net financial expenses (-) -46 -55 -17% -16% Result from associates -1 0 N/A N/A

Profit before income taxes 629 564 12% 17% Income tax expense (-) / credit -56 -114 -51% -49%

Profit from continuing operations 573 450 27% 33% Profit / loss (-) from discontinued operations 1 1 -44% -62%

Profit 574 451 27% 33% Attributable to UCB shareholders 551 431 28% 33% Attributable to non-controlling interests 23 20 15% 29%

Profit attributable to UCB shareholders 551 431 28% 33%

9M 2018 report2018 HY report: core earnings per share 38

Strong growth of core net profit

Numbers may not add due to roundingCER: constant exchange rateEPS: earnings per share

For the six months ended 30 June Actual Variance

€ million 2018 2017 Actual rates CER

Profit 574 451 27% 33% Attributable to UCB shareholders 551 431 28% 33% Attributable to non-controlling interests 23 20 15% 29%

Profit attributable to UCB shareholders 551 431 28% 33% Total non-recurring income (-) / expenses -19 -1 > 100% > 100% Income tax on non-recurring expenses (-) / credit 0 -1 -59% -59% Financial one-off income (-) / expenses 0 0 N/A N/A Income tax on financial one-off income / expenses (-) 0 0 N/A N/A Profit (-) / loss from discontinued operations -1 -1 -44% -62% Amortization of intangibles linked to sales 61 61 1% 5% Income tax on amortization of intangibles linked to sales -11 -12 -6% -5%

Core profit attributable to UCB shareholders 581 477 22% 27% Weighted average number of shares (million) 188 188 0%

Core EPS attributable to UCB shareholders 3.09 2.53 22% 27%

9M 2018 report

Numbers may not add due to roundingCER: constant exchange rate

2018 HY report: key product net sales performance 39

For the six months ended 30 June Actual Variance

€ million 2018 2017 Actual rates CER

Core products 1 801 1 741 3% 12% Immunology / CimziaP

® 679 663 2% 11% Neurology

VimpatP

® 522 477 10% 20% KeppraP

®P (including KeppraP

®P XR + E KeppraP

®P) 392 412 -5% 2%

NeuproP

® 148 154 -4% 0% BriviactP

® 60 36 67% 83% Established brands 280 302 -7% -3%

ZyrtecP

®P (including Zyrtec-DP

®P / CirrusP

®P) 58 61 -6% -3%

XyzalP

® 51 54 -6% 0% Other products 171 186 -8% -5%

Net sales before hedging 2 081 2 043 2% 10% Designated hedges reclassified to net sales 65 -8 > -100% Total net sales 2 146 2 036 5% 10%

9M 2018 reportOne UCB today: A global player 40

Presence in 38 countries complemented by a robust network of partners

Situation at 30 June 2018

7 480employees

globally

9M 2018 report 41Stable shareholder base with free-float of 62%Weighted average shares outstanding in 2018: 188 million

“Free float” investors by region

Source: Notifications, FactSet and UCB underlying ownership analysis, October 2018

9M 2018 report 42

Antje Witte, Vice President Investor Relations• Phone: +32 2 559 9414• E-mail: antje.witte@ucb.com

Neil Wallace, Director Investor Relations• Phone: +32 2 386 2869• E-mail: neil.wallace@ucb.com

Isabelle Ghellynck, Director Investor Relations Check out our IR App – stay• Phone: +32 2 559 9588 tuned wherever you go • E-mail: isabelle.ghellynck@ucb.com

Nathalie Deldime, Investor Relations Manager• Phone: +32 2 559 9291• E-mail: nathalie.deldime@ucb.com

Your UCB Investor Relations team